Active surveillance of lung subsolid nodules reduces unnecessary surgery and overtreatment

July 17, 2018, International Association for the Study of Lung Cancer

Subsolid nodules (SSN) can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance. Conservative management of SSN will reduce unnecessary surgery and overtreatment in patients with multiple comorbidities and aggressive lung cancer arising from lung sites other than the SSN.

Lung is the leading cause of cancer-related deaths in the world. Typically, symptoms of lung cancer don't appear until the disease is already at an advanced, non-curable stage. Lung cancer screening by low-dose computed tomography (LDCT) allows for early detection and early treatment of lung cancer thereby reducing lung cancer-related deaths. However, LDCT does have its limitations such as finding abnormalities that are noncancerous, requiring the patient to have additional testing, as well as diagnosing and treating malignancies that would have not affected the patient's life expectancy. Overdiagnosis and overtreatment are often seen in slow-growing lung adenocarcinomas represented by SSN. Unfortunately, the resection of SSN might not be clinically advantageous and may result in cardiopulmonary damage in with multiple comorbidities. Therefore, treatment by resection verses surveillance for persistent SSN remains controversial.

A group of European investigators evaluated the risk of lung cancer and lung cancer-related death in patients with unresected SSN over a period of almost 10 years, and analyzed whether cancer arose from the SSN. The aim was to determine the long-term outcome of patients with unresected SSN in . In 2005, the Multicenter Italian Lung Detection (MILD) screening trial implemented active surveillance for persistent SSN as opposed to early resection. The results of this study were based on the 2,303 patients randomized to the LDCT arm (age 58.1 ± 5.9 years, cumulative tobacco exposure 43.6 ± 21.5 pack years) of the MILD screening trial. Patients with SSN were selected by visual analysis and computer aided diagnosis (CAD). All SSN were classified into non-solid nodules (NSN) or part-solid nodules (PSN) and were measured by volumetric semi-automatic segmentation. The volume of SSN was measured including the whole non-solid component (NSN and PSN) and the solid component (PSN). The risk of overall mortality and lung cancer mortality was tested by Cox proportional hazards model.

The results of the study were published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC). A total of 6,541 nodules were detected in 55.5% (1,277/2,303) of the patients screened. Using both visual and CAD screening 16.9% of patients (389/2,303) were found to have a SSN. Thirty lung cancers were diagnosed in 389 patients with SSN, reflecting a 7.7% overall risk of being diagnosed with lung cancer throughout the 9.3 ± 1.2 years of follow-up and hazard ratio (HR) of 6.77 (95%CI: 3.39-13.54). Lung cancer not originating from the SSN was seen in 22/30 (73%) of patients with SSN. Lung cancer appeared after a median time of 52 months from detection of the SSN. The HR for lung cancer-specific mortality was 3.80 (95%CI: 1.24-11.65) for patients with SSN compared to patients without lung nodules. Lung cancer arising from SSN did not lead to death within the follow-up period in 100% of patients with SSN-derived lung cancer compared to 63.6% for lung cancers not derived from SSN.

The authors comment that, "In conclusion, the majority of subjects with SSN who were diagnosed with in the MILD cohort had developed a cancer elsewhere in the lungs. Lung cancers that arose from the SSN never represented the cause of death within the nearly 10-year follow-up period. Therefore, SSN can be considered a biomarker of cancer risk, and should be managed by active surveillance until signs of growth of the solid component. This approach will reduce unnecessary surgery with cardiopulmonary damage in subjects with multiple comorbidities, including more aggressive lung cancers arising from sites other than the SSN. We suggest that subjects with SSN might be a suitable target population for pharmacological smoking-cessation and chemoprevention trials."

Explore further: Prediction tool helps tailor lung cancer screening to patients

More information: Mario Silva et al. Long-term Active Surveillance of Screening Detected Subsolid Nodules is a Safe Strategy to Reduce Overtreatment, Journal of Thoracic Oncology (2018). DOI: 10.1016/j.jtho.2018.06.013

Related Stories

Prediction tool helps tailor lung cancer screening to patients

May 30, 2018
(HealthDay)—Personalizing the harm-benefit assessment of low-dose computed tomography (LDCT) screening for lung cancer can inform patient-centered screening decisions, according to a study published online May 29 in the ...

Researchers identify method to overcome false positives in CT imaging for lung cancer

May 15, 2018
A team of researchers including investigators from Mayo Clinic has identified a technology to address the problem of false positives in CT-based lung cancer screening. The team's findings are published in the current issue ...

Autoantibodies may help detect lung cancer earlier

February 17, 2016
Preliminary research has identified autoantibodies, immune proteins found in the blood specific for one's own proteins, that can potentially detect lung cancer early by distinguishing between smokers with or without lung ...

Risk-based CT screening may reduce deaths from lung cancer

January 1, 2018
Compared to National Lung Screening Trial criteria, targeting screening those at highest risk from lung cancer mortality using a risk prediction tool may improve efficiency in terms of greater reduction in mortality from ...

Canadian group gives guideline recommendations for lung cancer screening

September 4, 2013
Lung cancer is the most common cause of cancer death in Ontario. Screening for lung cancer using low-dose computed tomography (LDCT) has been the subject of many research studies since the 1990s. The National Lung Screening ...

Study highlights importance of regular lung cancer screenings for those at high risk

August 18, 2016
Lung cancer is the leading cause of cancer death for men and women. It is also one of the most complex cancers, both at the molecular level and through its clinical behavior. Screening is paramount as it helps physicians ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.